Health Canada approves darolutamide for metastatic castration-sensitive prostate cancer

prostate cancer, metastatic castration-sensitive prostate cancer, darolutamide, androgen deprivation therapy, radiographic progression-free survival, overall survival, safety, treatment-emergent adverse events

来源: urologytimes

原文链接：原文

参考文献

1. Health Canada grants marketing authorization for an additional indication of Bayer’s NUBEQA (darolutamide) for the treatment of metastatic castration-sensitive prostate cancer (mCSPC). News release. Bayer Inc. August 21, 2025. Accessed August 25, 2025. https://www.biospace.com/press-releases/health-canada-grants-marketing-authorization-for-an-additional-indication-of-bayers-nubeqa-darolutamide-for-the-treatment-of-metastatic-castration-sensitive-prostate-cancer-mcspc
2. Saad F, Vjaters E, Shore N, et al; ARANOTE Study Investigators. Darolutamide in combination with androgen-deprivation therapy in patients with metastatic hormone-sensitive prostate cancer from the phase III ARANOTE trial. J Clin Oncol. 2024;42(36):4271-4281. doi:10.1200/JCO-24-01798